Brian A Gordon

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8190805/brian-a-gordon-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 papers	4,585 citations	34 h-index	67 g-index
204 ext. papers	6,294 ext. citations	7 avg, IF	5.43 L-index

#	Paper	IF	Citations
185	Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. *Neurobiology of Aging*, **2022**, 112, 181-190	5.6	1
184	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.. *Journal of Clinical and Experimental Neuropsychology*, **2022**, 1-13	2.1	3
183	Variant-dependent heterogeneity in amyloid burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.. *Lancet Neurology, The*, **2022**, 21, 140-152	24.1	5
182	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. *Neurobiology of Disease*, **2022**, 105662	7.5	1
181	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. *Lancet Neurology, The* , **2022**, 21, 329-341	24.1	4
180	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer's disease.. *Neurobiology of Disease*, **2022**, 105714	7.5	0
179	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. *NeuroImage*, **2022**, 119228	7.9	1
178	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome.. *Frontiers in Neuroscience*, **2022**, 16, 795317	5.1	0
177	Effect of Race on Prediction of Brain Amyloidosis by Plasma A42/A40, Phosphorylated Tau, and Neurofilament Ligh.. *Neurology*, **2022**,	6.5	4
176	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). *Alzheimer Disease and Associated Disorders*, **2021**, 35, 164-168	2.5	9
175	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. *Brain*, **2021**, 144, 2176-2185	11.2	13
174	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. *Journal of Neuroimmunology*, **2021**, 352, 577474	3.5	0
173	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. *Brain Connectivity*, **2021**, 11, 239-249	2.7	5
172	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. *Neurology*, **2021**, 97, e76-e87	6.5	7
171	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. *Psychological Science*, **2021**, 32, 849-860	7.9	2
170	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nature Medicine*, **2021**, 27, 1187-1196	50.5	51
169	Comparing amyloid-plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. *Acta Neuropathologica*, **2021**, 142, 689-706	14.3	8

168	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. *Biological Psychiatry*, **2021**, 89, 776-785	7.9	13
167	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. *Molecular Psychiatry*, **2021**, 26, 614-628	15.1	34
166	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. *Journal of Cognitive Neuroscience*, **2021**, 33, 279-302	3.1	2
165	Cerebrospinal fluid A42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. *Neurobiology of Aging*, **2021**, 98, 116-123	5.6	2
164	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. *Annals of Neurology*, **2021**, 89, 254-265	9.4	13
163	Flortaucipir (tau) PET in LGI1 antibody encephalitis. *Annals of Clinical and Translational Neurology*, **2021**, 8, 491-497	5.3	2
162	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12197	5.2	
161	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nature Communications*, **2021**, 12, 5346	17.4	6
160	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. *Alzheimer's Research and Therapy*, **2021**, 13, 153	9	
159	Regional age-related atrophy after screening for preclinical alzheimer disease. *Neurobiology of Aging*, **2021**, 109, 43-51	5.6	1
158	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. *Neurology*, **2021**, 97, e1823-e1834	9.3	5
157	Modeling autosomal dominant Alzheimer's disease with machine learning. *Alzheimer's and Dementia*, **2021**, 17, 1005-1016	1.2	5
156	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. *Neurology*, **2021**, 96, e1632-e1645	6.5	4
155	Sharper in the morning: Cognitive sundowning revealed with high-frequency smartphone testing. *Alzheimer's and Dementia*, **2021**, 17,	1.2	1
154	Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center. *Alzheimer's and Dementia*, **2020**, 16, e037136	1.2	
153	Mass spectrometry measures of plasma A, tau and P-tau isoforms' relationship to amyloid PET, tau PET, and clinical stage of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e037518	1.2	0
152	Global system segregation enhances reserve in normal aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e037930	1.2	
151	Solanezumab in-depth outcomes. *Alzheimer's and Dementia*, **2020**, 16, e038028	1.2	2

150	Gantenerumab in-depth outcomes. *Alzheimer's and Dementia*, **2020**, 16, e038049	1.2	1
149	Tau kinetics in Alzheimer disease and primary tauopathies. *Alzheimer's and Dementia*, **2020**, 16, e039109	1.2	
148	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. *Alzheimer's and Dementia*, **2020**, 16, e041129	1.2	3
147	Socioeconomic status mediating sex and racial differences using the AT(N) framework. *Alzheimer's and Dementia*, **2020**, 16, e041229	1.2	1
146	Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e041586	1.2	1
145	Tauopathy in autosomal dominant and late-onset Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e041683	1.2	
144	APOE4 status influences the amyloid and tau relationship. *Alzheimer's and Dementia*, **2020**, 16, e042093	1.2	
143	Socioeconomic status mediates racial differences seen using the AT(N) framework. *Alzheimer's and Dementia*, **2020**, 16, e043216	1.2	
142	Head-to-head comparison of [18F]MK-6240 and [18F]flortaucipir (AV-1451) in autosomal dominant Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e044688	1.2	
141	Default mode network dedifferentiation predicts cognitive performance in Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e044790	1.2	
140	Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e045905	1.2	
139	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. *Alzheimer's and Dementia*, **2020**, 16, e045942	1.2	
138	Evaluation of 18F-MK-6240 and 18F-AV-1451 tau PET tracers in Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e046124	1.2	
137	Neurofilament light is a non-specific marker of aging and white matter integrity. *Alzheimer's and Dementia*, **2020**, 16, e046169	1.2	
136	Vasogenic edema in the frontostriatal tract and the anterior limb of the internal capsule predict cognitive decline in Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e046183	1.2	
135	A time-embedding network model captures dynamic longitudinal pathology changes in a dominantly inherited Alzheimer disease population. *Alzheimer's and Dementia*, **2020**, 16, e046335	1.2	
134	Investigating whether fractional anisotropy is associated with reduced reaction time cost on an attentional control task. *Alzheimer's and Dementia*, **2020**, 16, e046462	1.2	
133	A comparison of the Montreal Cognitive Assessment and standard cognitive measures in the National Alzheimer's Coordinating Center and Knight Alzheimer's Disease Research Center cohorts. *Alzheimer's and Dementia*, **2020**, 16, e046780	1.2	0

132	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 2475-2480	5.3	4
131	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. *Lancet Neurology, The*, **2020**, 19, 513-521	24.1	53
130	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. *Cerebral Cortex*, **2020**, 30, 5686-5701	5.1	14
129	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. *Neurobiology of Disease*, **2020**, 142, 104960	7.5	15
128	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. *NeuroImage: Clinical*, **2020**, 26, 102248	5.3	7
127	Neurofilaments in disease: what do we know?. *Current Opinion in Neurobiology*, **2020**, 61, 105-115	7.6	17
126	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*, **2020**, 26, 398-407	50.5	160
125	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 74, 1119-1129	4.3	4
124	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. *Neurobiology of Aging*, **2020**, 96, 165-175	5.6	1
123	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. *Brain Communications*, **2020**, 2, fcaa102	4.5	6
122	Predicting dysfunctional age-related task activations from resting-state network alterations. *NeuroImage*, **2020**, 221, 117167	7.9	12
121	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. *NeuroImage: Clinical*, **2020**, 28, 102491	5.3	4
120	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. *Neurobiology of Aging*, **2020**, 96, 233-245	5.6	6
119	Association between personality and tau-PET binding in cognitively normal older adults. *Brain Imaging and Behavior*, **2020**, 14, 2122-2131	4.1	11
118	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. *Alzheimer's and Dementia*, **2020**, 16, 501-511	1.2	20
117	Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. *Brain*, **2019**, 142, 2903-2904	11.2	1
116	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nature Medicine*, **2019**, 25, 277-283	50.5	375
115	Author response: In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. *Neurology*, **2019**, 92, 150	6.5	1

114	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-Burden in Cognitively Normal Individuals in Late-Life. *Journal of Alzheimer's Disease*, **2019**, 69, 817-827	4.3	9
113	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101767	5.3	16
112	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 180-190	5.2	46
111	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. *European Journal of Neurology*, **2019**, 26, 1235-1239	6	2
110	High-precision plasma -amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*, **2019**, 93, e1647-e1659	6.5	245
109	IC-P-166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS **2019**, 15, P131-P131		
108	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. *Brain*, **2019**, 142, 1063-1076	11.2	71
107	IC-P-131: PIB BINDING TOPOGRAPHY BEST CORRELATES WITH YOUNG ADULT GLYCOLYSIS **2019**, 15, P108-P108		
106	IC-P-094: CROSS-SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P82-P83		
105	IC-P-098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P85-P86		
104	O3-12-01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P914-P915		
103	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. *JAMA Network Open*, **2019**, 2, e1917126	10.4	15
102	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. *JAMA Neurology*, **2019**, 76, 264-273	17.2	117
101	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. *Neurobiology of Aging*, **2019**, 75, 42-50	5.6	26
100	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimer's and Dementia*, **2018**, 14, 1460-1469	1.2	120
99	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE 4 genotype. *Brain*, **2018**, 141, 1828-1839	11.2	53
98	Measures of metabolism provide insights into hippocampal sclerosis. *Brain*, **2018**, 141, 946-948	11.2	1
97	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurology, The*, **2018**, 17, 241-250	24.1	224

96	In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. *Neurology*, **2018**, 90, e896-e906	9.5	20
95	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid positron emission tomography pathology. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 245-252	5.2	34
94	Tau Kinetics in Neurons and the Human Central Nervous System. *Neuron*, **2018**, 97, 1284-1298.e7	13.9	208
93	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2018**, 67, 95-98	5.6	40
92	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World Journal of Biological Psychiatry*, **2018**, 19, 244-328	3.8	148
91	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*, **2018**, 91, e859-e866	6.5	116
90	Discovery and validation of autosomal dominant Alzheimer's disease mutations. *Alzheimer's Research and Therapy*, **2018**, 10, 67	9	16
89	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2018**, 61, 509-513	4.3	4
88	O3-13-03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2018**, 14, P1056-P1057		
87	IC-P-204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2018**, 14, P167-P168		0
86	P3-251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD **2018**, 14, P1170-P1170		1
85	IC-P-167: ALTERED RESTING-STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE **2018**, 14, P140-P140		
84	IC-P-162: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASIS-3 DATA **2018**, 14, P136-P137		
83	IC-P-207: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITY-BASED APPROACH **2018**, 14, P170-P171		
82	IC-P-009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD **2018**, 14, P19-P19		
81	IC-02-01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN **2018**, 14, P1-P2		
80	IC-P-042: RESTING-STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2018**, 14, P42-P43		
79	P2-362: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN **2018**, 14, P829-P830		

78	IC-P-043: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE **2018**, 14, P43-P43		
77	P4-108: RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2018**, 14, P1480-P1480		3
76	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 669-677	5.2	11
75	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 669-676	6	6
74	IC-04-02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETA-AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2018**, 14, P7-P8		
73	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. *Neurology*, **2018**, 91, e1295-e1306	6.5	129
72	Widespread distribution of tauopathy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2018**, 72, 177-185	5.6	26
71	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. *NeuroImage: Clinical*, **2018**, 19, 406-416	5.3	37
70	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. *Neurology*, **2018**, 91, e313-e318	6.5	43
69	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 87-93	2.5	37
68	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. *NeuroImage*, **2017**, 161, 171-178	7.9	76
67	[IC-P-057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P47-P47		
66	Left caudal middle frontal gray matter volume mediates the effect of age on self-initiated elaborative encoding strategies. *Neuropsychologia*, **2017**, 106, 341-349	3.2	7
65	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. *Neurobiology of Aging*, **2017**, 49, 216.e7-216.e13	5.6	13
64	[P2□72]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P768-P769		
63	[P1□08]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P233-P234		
62	[P2□74]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER **2017**, 13, P769-P770		
61	[P4□44]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN AD-DEFINED REGIONS **2017**, 13, P1370-P1371		

60 [IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P44-P45

59 [IC-P-061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P50-P50

58 [IC-P-064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD **2017**, 13, P53-P53

57 [IC-P-138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD **2017**, 13, P105-P105

56 [IC-P-166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P125-P126

55 [IC-P-180]: FLORTAUCIPIR TAU-PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDT-JAKOB DISEASE **2017**, 13, P134-P134

54 [IC-P-196]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER's DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER's DISEASE RESEARCH CENTER **2017**, 13, P144-P145

53 [IC-P-205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]-AV-1451 PET **2017**, 13, P149-P150

52 [IC-0102]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN AD-DEFINED REGIONS **2017**, 13, P1-P2

51 [IC-0202]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P4-P5

50 [P1351]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER **2017**, 13, P391-P392

49 [P1402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD **2017**, 13, P427-P428

48 [P1422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P440-P440

47 [P2345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P754-P754

46 [O1-02-01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD **2017**, 13, P184-P185

45 [O1-02-03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P186

44 [O2-05-03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING **2017**, 13, P561

43 [O3-09-05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]-AV-1451 PET **2017**, 13, P922

42	[IC-P-197]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER **2017**, 13, P145-P146		
41	[O1□02□04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P186-P187		
40	Longitudinal □Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. *JAMA Neurology*, **2016**, 73, 1192-1200	17.2	63
39	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. *Annals of Neurology*, **2016**, 80, 379-87	9.4	65
38	Tau and A□imaging, CSF measures, and cognition in Alzheimer's disease. *Science Translational Medicine*, **2016**, 8, 338ra66	17.5	418
37	IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42, and Cognition in Alzheimer□ Disease **2016**, 12, P130-P131		
36	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. *Brain*, **2016**, 139, 2249-60	11.2	125
35	Comparing Aging and Fitness Effects on Brain Anatomy. *Frontiers in Human Neuroscience*, **2016**, 10, 286	3.3	22
34	IC-P-117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study **2016**, 12, P87-P88		
33	P1-254: Principal Component Analysis of [18F]-Av-1451 TAU Pet in Alzheimer□ Disease and Frontotemporal Dementia **2016**, 12, P507-P508		
32	IC-P-098: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to The Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks **2016**, 12, P75-P75		
31	P3-234: Similarities and Differences in Patterns of [F18]-AV-1451 and [F18]-FDG in Frontotemporal Dementia **2016**, 12, P915-P916		
30	P3-283: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to the Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks **2016**, 12, P946-P946		
29	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimer□ Disease and Frontotemporal Dementia **2016**, 12, P145-P146		
28	IC-P-206: Similarities and Differences in Patterns of [F18]-Av-1451 And [F18]-FDG in Frontotemporal Dementia **2016**, 12, P147-P147		
27	O2-08-05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study **2016**, 12, P246-P246		
26	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. *Neurobiology of Aging*, **2016**, 44, 1-8	5.6	65
25	A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimer's disease: The adult children study. *Neuropsychology*, **2016**, 30, 225-38	3.8	23

24	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. *Neurobiology of Aging*, **2015**, 36, 1771-9	5.6	30
23	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology*, **2015**, 85, 790-8	6.5	23
22	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P41-P41		
21	O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers **2015**, 11, P122-P123		
20	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant **2015**, 11, P697-P697		
19	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. *NeuroImage: Clinical*, **2015**, 8, 246-52	5.3	32
18	IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers **2015**, 11, P24-P25		
17	IC-P-164: Patterns of tau binding in T807-PET imaging **2015**, 11, P110-P110		1
16	P2-154: Patterns of tau binding in T807-PET imaging **2015**, 11, P546-P546		
15	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P172-P172		
14	Prefrontal gray matter volume mediates age effects on memory strategies. *NeuroImage*, **2014**, 90, 326-34	7.9	41
13	Regional variability in Alzheimer's disease biomarkers. *Future Neurology*, **2014**, 9, 131-134	1.5	4
12	Spread of activation and deactivation in the brain: does age matter?. *Frontiers in Aging Neuroscience* , **2014**, 6, 288	5.3	9
11	Neurovascular coupling in normal aging: a combined optical, ERP and fMRI study. *NeuroImage*, **2014** , 85 Pt 1, 592-607	7.9	145
10	Evidence for a detrimental relationship between hypertension history, prospective memory, and prefrontal cortex white matter in cognitively normal older adults. *Cognitive, Affective and Behavioral Neuroscience*, **2013**, 13, 405-16	3.5	14
9	Effects of aging and Alzheimer's disease along the longitudinal axis of the hippocampus. *Journal of Alzheimer's Disease*, **2013**, 37, 41-50	4.3	23
8	he Effects of Aging and Physical Fitness on Working Memory Capacity. *Korean Journal of Cognitive and Biological Psychology*, **2012**, 24, 107-126	0.3	1
7	Structural correlates of prospective memory. *Neuropsychologia*, **2011**, 49, 3795-800	3.2	71

6	Span, CRUNCH, and beyond: working memory capacity and the aging brain. *Journal of Cognitive Neuroscience*, **2010**, 22, 655-69	3.1	272
5	Frequency analysis of the visual steady-state response measured with the fast optical signal in younger and older adults. *Biological Psychology*, **2010**, 85, 79-89	3.2	18
4	Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. *Psychophysiology*, **2008**, 45, 825-38	4.1	97
3	Effects of measurement method, wavelength, and source-detector distance on the fast optical signal. *NeuroImage*, **2006**, 32, 1576-90	7.9	103
2	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer disease, irrespective of fibrillar amyloid-beta pathology		3
1	Neuroimaging within the Dominantly Inherited Alzheimer Network (DIAN): PET and MRI		1